1109.5000 -1.30 (-0.12%)
NSE Jun 19, 2026 14:44 PM
Volume: 50,020
 

1109.50
-0.12%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma has gained 12.16% in the last 1 Week
More from Strides Pharma Science Ltd.
Recommended